{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "L858R",
          "alt": "R117H",
          "position": "117"
        },
        "variant_string_id": "LRRK2 L858R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with familial Parkinson’s disease and sporadic PD characterized by age-dependent dopaminergic neuron (DN) degeneration.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that LRRK2 mutations are linked to PD and that age-dependent DN degeneration is a key feature of this disease."
        },
        {
          "step_name": "Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper describes a ‘translationally repressed protein synthesis’ assay, which is relevant to LRRK2 action and potential neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The paper uses the translationally repressed protein synthesis assay, directly linking it to LRRK2's influence on protein production and potentially contributing to neuronal dysfunction."
        },
        {
          "step_name": "Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper specifies that this assay was performed in Drosophila e2f1 and dp mRNAs, which are translationally repressed by let-7 and miR-184*, indicating a significant impact on protein levels.",
          "judgment": "Yes",
          "reasoning": "The paper describes an assay using these mRNA targets, demonstrating a mechanistic link between LRRK2 and protein synthesis disruption."
        },
        {
          "step_name": "Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper details that the LRRK2 mutation affects protein synthesis and potentially contributes to the pathogenesis of PD. It suggests that LRRK2 interacts with the microRNA pathway to regulate protein production.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that LRRK2 interacts with the microRNA pathway, explaining a crucial mechanism of action related to protein synthesis."
        },
        {
          "step_name": "Evaluate the strength of functional evidence",
          "extracted_paper_info": "The paper suggests that LRRK2 antagonizes these miRNAs, leading to overproduction of E2F1/DP previously implicated in cell cycle and survival control. This suggests a key role in LRRK2 pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper highlights the antagonistic relationship between LRRK2 and these miRNAs, linking it to a mechanistic pathway of PD progression."
        },
        {
          "step_name": "Evaluate the strength of the functional evidence",
          "extracted_paper_info": "The paper states that this LRRK2 phenotype is critical for LRRK2 pathogenesis, which supports a significant impact of LRRK2 in driving disease progression.",
          "judgment": "Yes",
          "reasoning": "The paper claims the LRRK2 phenotype is a key driver of the disease progression."
        },
        {
          "step_name": "Next Steps",
          "extracted_paper_info": "The paper details LRRK2's association with Argonaute-1 (dAgo1) or human Argonaute-2 (hAgo2) of the RNA-induced silencing complex (RISC).",
          "judgment": "Yes",
          "reasoning": "The data clearly shows a direct relationship between LRRK2 and the RISC."
        },
        {
          "step_name": "Determine the overall conclusion",
          "extracted_paper_info": "The LRRK2 mutation leads to aberrant synthesis of E2F1/DP, and suggests novel miRNA-based therapeutic strategies.",
          "judgment": "Yes",
          "reasoning": "The paper clearly identifies LRRK2 as a driver of this pathway and highlights a potential therapeutic opportunity."
        }
      ]
    }
  ]
}